Important Issues in Patient Reported Outcomes (PRO) Research
|
|
- Homer Casey
- 6 years ago
- Views:
Transcription
1 Important Issues in Patient Reported Outcomes (PRO) Research Feb. 16, 2001 Organized by The Harmonization Coordination Committee Representing European Regulatory Issues on Quality-of of-life Assessment (ERIQA), International Society of Pharmacoeconomic and Outcomes Research (ISPOR), Pharmaceutical Research and Manufacturers of America (PhRMA( PhRMA) ) Health Outcomes Committee (HOC), and International Society of Quality of Life (ISOQOL) 1 02/16/01
2 History Two Harmonization meetings held!march 31, 2000!Sept. 14, 2000 Representatives from ERIQA, ISOQOL, ISPOR, PhRMA HOC, and FDA observers 2 02/16/01
3 Objectives Discuss problematic issues Harmonize recommendations proposed by each organization Discuss solutions when no recommendations suggested Proposed future steps to achieve consensus on problematic issues 3 02/16/01
4 First Meeting Outcomes Consensus and areas of disagreement were identified in four areas: Concept, Study Design, Interpretation and Conditions for Claims* Group agreed to continue discussion and form a coordination group with representatives from the four organizations to organize future meetings *Report available on-line: /16/01
5 2 nd Meeting Outcomes Conceptual framework was broadened to Patient Based Assessment (PBA) which was changed to Patient Reported Outcomes (PR0) for clarity Decision made to continue discussions and schedule meeting with FDA and EMEA representatives 5 02/16/01
6 Today s Meeting Objectives Clarify aspects and components of PRO evaluation Discuss where PRO can add value to clinical endpoints Suggest use of this information within labeling and promotional claims 6 02/16/01
7 Meeting Agenda 08:45 09:15 Group 1 09:15-10:00 Group 2 10:00-10:15 Break 10:45 11:00 Group 4 11:00 11:15 Next Steps 11:15 11:45 Discussion 10:15-10:45 Group /16/01
8 Take Away Points Patient has a unique voice and valuable perspective that should play a role in medical decision making PROs can be measured in reliable and valid ways PROs are increasingly used as efficacy endpoints in randomized controlled trials 8 02/16/01
9 GROUP 1: Conceptual and Definitional Issues Team Leader: Margaret Rothman, Ph.D Members:! Ivan Barofsky, Ph.D! Pennifer Erickson, Ph.D! Paul Kind, M.Phil! Donald Patrick, Ph.D, M.S.P.H. 9 02/16/01
10 Patient Outcomes Assessment Sources and Examples Clinician - Reported Physiological Caregiver - Reported Patient - Reported For example, Global impressions Observation & tests of function For example, FEV 1 HbA1c Tumor size For example, Dependency Functional status For example, Functional status Symptoms HRQL 10 02/16/01
11 Patient Outcomes Assessment Sources and Examples Clinician- Reported Physiological Caregiver - Reported Patient - Reported Global Impression Functional status Well-being Symptoms HRQL Satisfaction with TX Treatment adherence 11 02/16/01
12 Health-Related Quality of Life: One Type of PRO Represents the patient s evaluation of the impact of a health condition and its treatment on relevant aspects of life 12 02/16/01
13 Health-Related Quality of Life: Essential Elements Represents the patient s evaluation of the impact of a health condition and its treatment on relevant aspects of life The evaluative component can be measured by severity bothersomeness importance or satisfaction 13 02/16/01
14 Health-Related Quality of Life: Essential Elements Represents the patient s evaluation of the impact of a health condition and its treatment on relevant aspects of life The relevant aspects of life are measured as domains, e.g., physical psychological social symptoms 14 02/16/01
15 Health-Related Quality of Life: Essential Elements Represents the patient s evaluation of the impact of a health condition and its treatment on relevant aspects of life Domains are selected to be relevant to patients and their significant others, e.g., focus groups cognitive interviews literature reviews 15 02/16/01
16
17 GROUP 2:The Value of Patient Reported Outcomes Team Leader: Nancy Kline Leidy, Ph.D Members:! Asha Hareendarn, M.D.! Charlotte McMillan, Ph.D! David Miller, Ph.D! Dennis Revicki, Ph.D! Pierre Sagnier, M.D.! Ingela Wiklund, Ph.D 17 02/16/01
18 The Patient s Perspective is... A unique indicator of the impact of disease Essential for evaluating treatment efficacy Useful for interpreting clinical outcomes A key element in treatment decision-making 18 02/16/01
19 PROs May be the Sole Indicator of Disease Activity Patient-reported symptoms rhinitis, migraine, functional gastrointestinal disorders, menopause, pain Patient-reported functioning sexual dysfunction, insomnia 19 02/16/01
20 PROs is Key Indicator of Disease Activity Patient-reported symptoms COPD, asthma, psoriasis, atopic dermatitis, benign prostatic hypertrophy Patient-reported functioning Parkinson s disease, MS, arthritis, cancer, stroke, traumatic brain injury 20 02/16/01
21 PROs Supplement Traditional Indicators PROs and traditional markers of disease activity are related, but not perfectly correlated daily functioning & FEV-1 r = 0.10 to 0.30 shared variance = 9% Thus, the two indicators are complementary 21 02/16/01
22 Objective Subjective Exercise test versus physical functioning, r = /16/01 Wiklund I et al. Clin Cardiol 1991;14
23 The Patient s Perspective is... A unique indicator of the impact of disease Essential for evaluating treatment efficacy Useful for interpreting clinical outcomes A key element in treatment decision-making 23 02/16/01
24 PROs are essential endpoints in clinical trials when... the patient s self-report is the primary or sole indicator of disease activity the treatment has a small impact on survival it is important to ensure that treatments do not adversely affect patients lives the study is an equivalence trial where the drug under study has PRO benefits 24 02/16/01
25 Migraine-Specific Quality of Life Questionnaire 21 Mean +/- S.E. Difference at 24 Hours Domain Score Placebo rizatr iptan 2.5 mg Work Functioning Social Functioning Energy/ Vitality Migraine Symptoms Feelings/ Concerns rizatr iptan 5 mg 25 02/16/01 rizatr iptan 10 mg Note: Patients assigned to the placebo group had the option to take rizatriptan 10 mg at 2 hours.
26 PROs Provide Supplemental Information In advanced breast cancer, continuous chemotherapy led to better HRQL than intermittent chemotherapy (Coates et al., 1987) standard-dose chemotherapy led to better HRQL than half-dose chemotherapy (Tannock et al., 1988) In soft tissue sarcoma of the limbs, amputation of the affected limb led to better HRQL than limb-sparing surgery plus adjuvant therapy (Sugarbaker et al., 1982) 26 02/16/01
27 The Patient s Perspective is... A unique indicator of the impact of disease Essential for evaluating treatment efficacy Useful for interpreting clinical outcomes A key element in treatment decision-making 27 02/16/01
28 Interpreting Clinical Outcomes in Terms of Patient Benefit Improvement in FEV-1 Effect on daily activity? Reduction in seizure frequency Effect on social functioning & well-being? 28 02/16/01
29 HRQL Outcomes of Seizure Responders by Treatment Group Total Score Seizure Worry Cognitive Funciton Medical Effects Social Function Health Status Placebo LEV 1000 mg LEV 3000 mg Cramer et al., Epilepsia, 41 (7): , 2000
30 The Patient s Perspective is... A unique indicator of the impact of disease Essential for evaluating treatment efficacy Useful for interpreting clinical outcomes A key element in treatment decision-making 30 02/16/01
31 PROs in Clinical-Decision Making Treatment Guidelines Oncology - ASCO Respiratory Disease Practice Guidelines - COPD, Asthma Gastrointestinal Disease - IBS Practice Guidelines - GERD Cardiovascular Disease Vascular Surgeons; Atrial Fibrillation Urology - BPH, urinary incontinence HIV- DHHS Panel Guidelines 31 02/16/01
32 PRO Data... Are necessary for clinical decision-making Must be communicated to decision makers clinicians, patients, payers scientific dissemination is insufficient Therefore... The FDA should not only allow, but encourage PRO evidence in product labels and promotion 32 02/16/01
33 The Patient s Perspective is... A unique indicator of the impact of disease. Essential for evaluating treatment efficacy. Useful for interpreting clinical outcomes. A key element in treatment decision-making /16/01
34
35 Break 35 02/16/01
36 GROUP 3: Methodological Considerations in Obtaining PROs in Clinical Trials Team Leader: Patrick Marquis, M.D. Members:! Olivier Chassany, M.D.! Dominique Dubois, M.D.! Joseph Jackson, Ph.D! Nancy Santanello, M.D., M.S.! Rhys Williams, Ph.D 36 02/16/01
37 Development and Validation of PRO Measures PROs are scientific measures that can evaluate change in outcomes Based on a recognized psychometric theory and methods (Likert 1932, Murphy 1937, McIver 1981, Nunnally 1994, 3rd edition) Supported by empirical validation Reliability, validity, responsiveness (Lohr 1996, Cronbach 1955, Goodwin 1997) 37 02/16/01
38 Implementation, analysis and reporting of PRO data - 1 Endpoint specification (What is the claim you are hoping to achieve? What are the measures and research questions that address that claim?) PRO selection and/or development (PRO demonstrates appropriate methods of measurement) PRO validation (Provide evidence of PRO validation) Study design (Appropriately addresses issues that have the potential to compromise the integrity of study - eg. randomization, administration methods, handling of missing data, etc.) 38 02/16/01
39 Implementation, analysis and reporting of PRO data - 2 Data analysis (pre-specified PRO analytic procedures for pre-specified claim) Interpretation of results (What do the results mean in the context of the clinical trial findings?) Reporting of results in approved labeling or promotion (full disclosure of all PRO results, PRO used, avoid implied terms) 39 02/16/01
40 Patient Reported Outcome Measures - Conclusions - PROs are scientific measures that can evaluate change in outcomes Handle like any other measures in clinical trials (physiologic, caregiver, clinician, measures) Methods for selecting, developing, validating, measuring, reporting, PROs are the same as other 40 02/16/01 clinical measures
41
42 GROUP 4: Interest and Demand for PRO Information Team Leader: Rick Berzon, Ph.D Members:! Joyce Cramer, Ph.D! Greg Boyer, Ph.D! Haim Erder, Ph.D! Albert Wu, M.D., Ph.D! Jean-Paul Gagnon, Ph.D! Richard Willke, Ph.D 42 02/16/01
43 Current trends that drive demand for PRO Chronic Illness Increasing prevalence and greater longevity with chronic illnesses Cure often not achievable for chronic illness Improving functioning and well-being are goals for new therapies for chronic illnesses (e.g., epilepsy, HIV/AIDS, cancers) 43 02/16/01
44 Patients want PRO Increases patient participation and voice in health care decision-making Patients decisions are based not on clinical outcomes alone More complete and relevant information for patients PROs have intuitive value to patients PROs provide insights to patients regarding treatment risks vs. benefits 44 02/16/01
45 Clinicians want PRO Willingness to allow patients to select among treatments based on potential for efficacy, adverse events and tolerability PRO assists in value-based, bottom line decisions for prescribers and payers, as well as for clinicians and patients 45 02/16/01
46 Patient Empowerment: Cancer Breast cancer patients: Greater patient involvement in decisionmaking leads to more limited surgery (Curran et al. Eur J Ca 1998; 34: ) Prostate cancer patients: Greater patient awareness of treatment options allows the patient to select and tailor individual treatment (Osoba et al. J Clin Oncol 1999; 17: ) 46 02/16/01
47 Example of Added Value from PRO: Alzheimer s Disease Efficacy outcomes are patient memory, cognition PROs are patient dignity, caregiver burden Medications slow progression and allow patients to remain home longer " caregiver burden " societal burden by delaying need for nursing home placement Patients and caregivers should know the impact of the treatment on outcomes in addition to measures of cognition (Shikiar et al. J Am Geriatr Soc 2000; 48: ) 47 02/16/01
48
49 Take Away Points Patient has a unique voice and valuable perspective that should play a role in medical decision making PROs can be measured in reliable and valid ways PROs are increasingly used as efficacy endpoints in randomized controlled trials 49 02/16/01
50 Next Step Hold meetings with FDA and EMEA representatives to expand discussions 50 02/16/01
51 Questions Does FDA accept that the validity, reliability and sensitivity of PRO data can be established to a degree sufficient for use in labeling and promotion 51 02/16/01
52 Questions Does FDA accept that in general PRO data may provide unique and valid information for use in product labels that is distinct from traditional clinical endpoints, or does its relevance have to be established on a case-by-case basis? 52 02/16/01
53 Questions What are FDA s intentions toward issuing a PRO guidance that is applicable across all reviewing divisions? 53 02/16/01
54 QUESTIONS AND DISCUSSION 54 02/16/01
Guidance for the improved integration of Health-Related Quality of Life assessment in the drug regulatory process
Guidance for the improved integration of Health-Related Quality of Life assessment in the drug regulatory process The ERIQA* Working Group experience * European Regulatory Issues on Quality of life Assessment
More informationEducational Program on Patient-Reported Outcomes (PROs) in Clinical Trials
SEMINAR May 23, 2003 09:00-16:45 pm INAMI, 211 Tervueren Av, BRUSSELS Educational Program on Patient-Reported Outcomes (PROs) in Clinical Trials Facilitators Catherine Acquadro, Olivier Chassany Introductions
More informationWhy use PROs? The relation to clinical outcomes
Introduction to Patient-Reported Outcomes (PROs) March 2-4 2004, Sigtuna, Sweden Why use PROs? The relation to clinical outcomes Olivier CHASSANY, MD, PhD Medical Manager, Clinical Research Dept (institutional
More informationAddressing Content Validity of PRO Measures: The Unique Case of Rare Diseases
Disclaimer: Presentation slides from the Rare Disease Workshop Series are posted by the Kakkis EveryLife Foundation, for educational purposes only. They are for use by drug development professionals and
More informationPATIENT REPORTED OUTCOMES
Introduction to Clinical Research: A Two-week Intensive Course PATIENT REPORTED OUTCOMES Albert W. Wu, MD, MPH Overview 1. Importance of patient perspective 2. Definitions 3. Key concepts to measure as
More informationDonald L. Patrick PhD, MSPH, Laurie B. Burke RPh, MPH, Chad J. Gwaltney PhD, Nancy Kline Leidy PhD, Mona L. Martin RN, MPA, Lena Ring PhD
Content Validity: Establishing and Reporting the Evidence in Newly-Developed Patient-Reported Outcome (PRO) Instruments for Medical Product Evaluation - Good Research Practices Donald L. Patrick PhD, MSPH,
More informationTask Force Background Donald Patrick. Appreciation to Reviewers. ISPOR PRO GRP Task Force Reports
Content Validity: Establishing and Reporting the Evidence in Newly-Developed Patient-Reported Outcome (PRO) Instruments for Medical Product Evaluation - Good Research Practices Donald L. Patrick PhD, MSPH,
More informationBackground to the Task Force. Introduction
Volume 12 Number 8 2009 VALUE IN HEALTH Use of Existing Patient-Reported Outcome (PRO) Instruments and Their Modification:The ISPOR Good Research Practices for Evaluating and Documenting Content Validity
More informationStudy Endpoint Considerations: Final PRO Guidance and Beyond
Study Endpoint Considerations: Final PRO Guidance and Beyond Laurie Burke Associate Director for Study Endpoints and Labeling OND/CDER/FDA Presented at: FIRST ANNUAL PATIENT REPORTED OUTCOMES (PRO) CONSORTIUM
More informationAdvancing the Science of Patient Input in Medical Product R&D: Towards a Research Agenda
Advancing the Science of Patient Input in Medical Product R&D: Towards a Research Agenda Session 1: Understanding Patient Experience with Disease or Medical Condition Theresa Mullin, PhD Associate Director
More informationPatient-Reported Outcomes (PROs) and the Food and Drug Administration Draft Guidance. Donald L. Patrick University of Washington
Patient-Reported Outcomes (PROs) and the Food and Drug Administration Draft Guidance Paul-Martini-Stiftung Berlin-Brandenburgische Akademie der Wissenschaften 6 March 2008 10:45 11:05 Donald L. Patrick
More informationPatient Reported Outcomes
Date Patient Reported Outcomes Presented by: Ari Gnanasakthy RTI Health Solutions 9 th Feb 2015 RTI Health Solutions Research Triangle Park, NC, USA Ann Arbor, MI, USA Barcelona, Spain Ljungskile, Sweden
More informationMeasuring outcomes to improve the management of continence care. Dr Adrienne Rivlin KPMG Global Strategy Group
Measuring outcomes to improve the management of continence care Dr Adrienne Rivlin KPMG Global Strategy Group Background of the study Many treatment options, few find a cure High quality daily continence
More informationBarbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi
Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Joseph T. DiPiro, PharmD, FCCP Panoz Professor of Pharmacy, College
More informationHealth authorities are asking for PRO assessment in dossiers From rejection to recognition of PRO
UNDERSTANDING AND ADDRESSING POTENTIAL BIAS IN PATIENT-REPORTED OUTCOMES FROM CLINICAL TRIALS ISPOR Barcelona Workshop Tuesday 13 November 14:00-15:00 Prof. Olivier Chassany EA 7334, Patient-Centered Outcomes
More informationClinician-reported Outcomes (ClinROs), Concepts and Development
Clinician-reported Outcomes (ClinROs), Concepts and Development William Lenderking, PhD, Senior Research Leader; Dennis Revicki, PhD, Senior Vice President, Outcomes Research In heathcare, there are many
More informationCaring for Survivors. Nancy Houlihan, RN, MA, AOCN. Cancer Survivorship Program
Caring for Survivors Nancy Houlihan, RN, MA, AOCN Cancer Survivorship Program Survivors Growing numbers of survivors Convergance of ageing population and numbers surviving cancer Greatest number are over
More informationPharmacotherapy Handbook
Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University
More informationWORK PLAN FOR THE EFFICACY WORKING PARTY (EWP) CHAIRPERSON: Barbara van Zwieten-Boot
European Medicines Agency London, 17 December 2009 EMA/CHMP/EWP/248088/2009 Rev. 1 WORK PLAN FOR THE EFFICACY WORKING PARTY (EWP) 2010 CHAIRPERSON: Barbara van Zwieten-Boot 1. MEETINGS SCHEDULED FOR 2010
More informationHow to incorporate Patient- Reported Outcomes (PROs) in Cochrane reviews? Caroline Terwee, Donald Patrick, Gordon Guyatt, Riekie de Vet
How to incorporate Patient- Reported Outcomes (PROs) in Cochrane reviews? Caroline Terwee, Donald Patrick, Gordon Guyatt, Riekie de Vet Aim of the workshop To provide some guidelines for how PROs can be
More informationMaking Economic Evaluation Fit for Purpose to Guide Resource Allocation Decisions
Making Economic Evaluation Fit for Purpose to Guide Resource Allocation Decisions Mark Sculpher, PhD Professor of Health Economics Centre for Health Economics University of York, UK Outline Policy context
More informationOpportunities and Challenges in the Development of Companion Diagnostics
Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine
More informationin alphabetical order:
FORUM 1 in alphabetical order: 2 Laurie B. Burke, RPh, MPH, Founder, Lora Group, LLC, Royal Oak, MD, USA and Affiliate Associate Professor, University of Maryland School of Pharmacy Stefan Cano, PhD, CPsychol,
More informationPatient-Reported Outcomes to Support Medical Product Labeling Claims: FDA Perspective
Volume 10 Supplement 2 2007 VALUE IN HEALTH Patient-Reported Outcomes to Support Medical Product Labeling Claims: FDA Perspective Donald L. Patrick, PhD, MSPH 1, Laurie B. Burke, RPh, MPH, 2 John H. Powers,
More informationWestern University of Health Sciences, College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of
Western University of Health Sciences, College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Topic UAN# Target Audience A
More informationA Framework for Patient-Centered Outcomes Research
A Framework for Patient-Centered Outcomes Research David H. Hickam, MD, MPH Director of Research Methodology, PCORI Baltimore, MD August 9, 2016 Session Faculty Disclosures David H. Hickam, MD, MPH No
More informationLECOM Health Ophthalmology
Patient Name: Date of Birth: New Patient Questionnaire Your answers will be used by your healthcare provider get an accurate history of your medical conditions and ocular concerns. If you are uncomfortable
More informationA Review of Patient-Reported Outcome Labeling in the United States ( ) Joseph C. Cappelleri Pfizer Inc
A Review of Patient-Reported Outcome Labeling in the United States (2011-2015) Joseph C. Cappelleri Pfizer Inc Invited oral presentation at the American Statistical Association Biopharmaceutical Section
More informationConsiderations for requiring subjects to provide a response to electronic patient-reported outcome instruments
Introduction Patient-reported outcome (PRO) data play an important role in the evaluation of new medical products. PRO instruments are included in clinical trials as primary and secondary endpoints, as
More informationMEASURING PATIENT AND OBSERVER-REPORTED OUTCOMES (PROS AND OBSROS) IN RARE DISEASE CLINICAL TRIALS - EMERGING GOOD PRACTICES TASK FORCE
MEASURING PATIENT AND OBSERVER-REPORTED OUTCOMES (PROS AND OBSROS) IN RARE DISEASE CLINICAL TRIALS - EMERGING GOOD PRACTICES TASK FORCE Outline I. Introduction: Current environment of clinical research
More informationPatient-Centered Endpoints in Oncology
Patient-Centered Endpoints in Oncology SIXTH ANNUAL PATIENT-REPORTED OUTCOME CONSORTIUM WORKSHOP April 29-30, 2015 Silver Spring, MD Disclaimer The views and opinions expressed in the following slides
More informationMRg HIFU: Current and future trends of MR guided Focused Ultrasound in Radiation Oncology. Arik Hananel MD, MBA, BsCs
MRg HIFU: Current and future trends of MR guided Focused Ultrasound in Radiation Oncology Arik Hananel MD, MBA, BsCs Disclosure InSightec http://www.insightec.com Focused Ultrasound Foundation http://www.fusfoundation.org
More informationOral Therapies: Strategies to Ensure Adherence Jan Tipton, MSN, RN, AOCN University of Toledo Medical Center
Oral Therapies: Strategies to Ensure Adherence Jan Tipton, MSN, RN, AOCN University of Toledo Medical Center Learning Objectives Review strategies, tools, and resources to facilitate adherence among patients
More informationDepression in the Medically Ill
Mayo School of Continuous Professional Development Psychiatry in Medical Settings February 9 th, 2017 Depression in the Medically Ill David Katzelnick, M.D. Professor of Psychiatry, Mayo Clinic College
More informationSAMPLE SIZE, GROUNDED THEORY, AND SATURATION IN COA DEVELOPMENT. Guidance for Industry: Sample size
SAMPLE SIZE, GROUNDED THEORY, AND SATURATION IN COA DEVELOPMENT Kathryn E. Lasch, PhD Pharmerit International Executive Director, PRO/COA and Qualitative Research May 23, 2018 ISPOR 2018 Baltimore 1 Guidance
More informationHEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018 WALK INS ARE ACCEPTED BUT WE ADVISE STUDENTS TO PRE-REGISTER BEFORE THURSDAY
SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs January 201 DATE DAY TIME TOPICS January 04 January 11 January 1 January 25 9:00AM 9:00AM 9:00AM 9:00AM 1. Understanding Fibromyalagia 2. Diabetes
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2019
January 2019 DATE DAY TIME TOPICS TOTAL January 03 1. Alcoholism 2. Nutrition for the Elderly 3. Uterine Fibroids 4. HIPAA 5.Arthritis 6. Childhood Obesity January 10 1. Understanding Epilepsy: Latest
More informationEMEA and the Regulatory Environment?
INTRODUCTION TO PATIENT-REPORTED OUTCOMES (PROs) SUCH AS HEALTH-RELATED QUALITY OF LIFE, TREATMENT SATISFACTION, ETC EMEA and the Regulatory Environment? A Review of the EMEA Notes for Guidance ERIQA Group
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018
January 201 DATE DAY TIME TOPICS TOTAL January 04 1. Understanding Fibromyalagia 2. Diabetes and Cardiovascular Disease 3. Prostate Cancer 4. Hepatitis C 5. Understanding Hepatitis B January 11 1. Dysphagia
More informationGuideline Summary Code Guideline Title Keyword Practice guideline for the treatment of patients with obsessivecompulsive.
Guideline Summary Code Guideline Title Keyword Practice guideline for the treatment of patients with obsessivecompulsive disorder. Found in Folder # obsessive compulsive disorder 1 NGC-5841 Delirium and
More informationHealth-Related Quality of Life and Patient-Reported Outcomes A European Perspective
ISPOR Fourth Annual European Congress Cannes, 11-13 November 2001 INTEGRATION OF PATIENT PERSPECTIVES IN DRUG EVALUATION: HARMONIZATION, CONSENSUS, AND DIVERGENCE Health-Related Quality of Life and Patient-Reported
More informationPharmacy Prep. Qualifying Pharmacy Review
Pharmacy Prep 2014 Misbah Biabani, Ph.D Director, Tips Review Centres 5460 Yonge St. Suites 209 & 210 Toronto ON M2N 6K7, Canada Luay Petros, R.Ph Pharmacy Manager, Wal-Mart, Canada 1 Disclaimer Your use
More informationNurseAchieve. CHAPTERS INCLUDED IN THE NURSEACHIEVE COMPREHENSIVE NCLEX REVIEW NURSING SKILLS AND FUNDAMENTALS:
NurseAchieve www.nurseachieve.com CHAPTERS INCLUDED IN THE NURSEACHIEVE COMPREHENSIVE NCLEX REVIEW NCLEX TEST STRATEGIES: NCLEX EXAM OVERVIEW TEST TAKING STRATEGIES NURSING SKILLS AND FUNDAMENTALS: ADMINISTRATION
More informationWhat is a Special Interest Group (SIG)?
PATIENT REPORTED OUTCOMES RESEARCH SPECIAL INTEREST GROUP Open Meeting 20 th Annual European Congress November 6, 2017 Glasgow, Scotland What is a Special Interest Group (SIG)? Member-driven group interested
More informationThe Regulation of Patient-Reported Outcome Claims: Need for a Flexible Standard
Volume 5 Number 4 2002 VALUE IN HEALTH The Regulation of Patient-Reported Outcome Claims: Need for a Flexible Standard Louis A. Morris, PhD, 1 David W. Miller, PhD 2 1 Louis A. Morris & Associates, Inc.,
More informationMORECare: A framework for conducting research in palliative care
MORECare: A framework for conducting research in palliative care Nancy Preston International Observatory on End of Life Care School of Nursing, Midwifery and Social Work Methods for evaluating service
More informationEstimands and Their Role in Clinical Trials
Estimands and Their Role in Clinical Trials Frank Bretz (Novartis) EFSPI/PSI UK September 28, 2015 Acknowledgements ICH E9(R1) Expert Working Group M Akacha, D Ohlssen, H Schmidli, G Rosenkranz (Novartis)
More informationDeveloping a Pediatric COA Measurement Strategy A Case Study in Asthma
Developing a Pediatric COA Measurement Strategy A Case Study in Asthma FIFTH ANNUAL PATIENT-REPORTED OUTCOME (PRO) CONSORTIUM WORKSHOP April 29-30, 2014 Silver Spring, MD Co-sponsored by Disclaimer The
More informationPatient-reported Outcomes
3 Patient-reported Outcomes Ingela Wiklund Key points Many gastrointestinal diseases are symptomdriven, so the patient s perspective is particularly important in this area. Patient-reported outcomes (PROs)
More informationCity State Zip. Cell Phone. Other Phone. Gender Male Female Status Single Married Divorced Widowed. Height Weight EXERCISE Yes No Times per Week
Patient Name (First Middle Last) Date of Birth Social Security # Address City State Zip Home Phone Work Phone Cell Phone Other Phone Email Place of Birth Occupation Retired Yes No Gender Male Female Status
More informationValue-based frameworks in oncology
28 November 2017 Value-based frameworks in oncology Clarity or confusion? Prepared for: European Statistical Meeting on Latest Trends in HTA Prepared by: Jan McKendrick, Senior Director PRMA Consulting
More informationCHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER
RAND WATER MEDICAL SCHEME RAND WATER MEDICAL SCHEME CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER LIST OF CHRONIC CONDITIONS Conditions covered under s chronic medication benefit are detailed below.
More informationJuly 7, Dear Sir or Madam:
Docket No. FDA-2017-D-2497 for Draft Revisions to FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioids; Request for Comments. American Society of Acupuncturists c/o David
More informationCost-of-Illness Summaries for Selected Conditions
January 2006 RTI International RTI-UNC Center of Excellence in Health Promotion Economics Costs (in billions of $) Costs adjusted to 2004 (in billions of $) Disease Total Direct Indirect Intangible Total
More informationProfessor Karl Claxton, Centre for Health Economics, University of York
Welcome to the InstEAD Annual Lecture 2014 Professor Karl Claxton, Centre for Health Economics, University of York Health (and ethics) Needs Economics: Which Health Technologies, at What Price and for
More informationFROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL CONFERENCE 2018
FOR IMMEDIATE RELEASE CONTACT: Alzheimer s Association AAIC Press Office, 312-949-8710, aaicmedia@alz.org Niles Frantz, Alzheimer s Association, 312-335-5777, nfrantz@alz.org FROM THE ALZHEIMER S ASSOCIATION
More informationGERIATRIC MEDICINE FOR PRIMARY CARE. Chicago, Illinois The Gwen, A Luxury Collection Hotel, Chicago June 22 24, 2018
GERIATRIC MEDICINE FOR PRIMARY CARE Chicago, Illinois The Gwen, A Luxury Collection Hotel, Chicago June 22 24, 2018 Friday, June 22nd: 7:30 am 8:00 am Registration and Hot Breakfast 8:00 am 9:00 am Faculty
More informationClinical Trial Endpoints from Mobile Technology: Regulatory Considerations September 29, 2016
Clinical Trial Endpoints from Mobile Technology: Regulatory Considerations September 29, 2016 Elektra J. Papadopoulos, MD, MPH Clinical Outcome Assessments Staff Office of New Drugs Center for Drug Evaluation
More informationPersonalized Medicine Where Traditional Chinese Medicine and Western Medicine Can Meet
Personalized Medicine Where Traditional Chinese Medicine and Western Medicine Can Meet Dr. Jean Paul Collet MD, PhD, Prof. - University of British Columbia - Child and Family Research Institute - BC Children
More informationCancer Chemotherapy in Clinical Practice
Cancer Chemotherapy in Clinical Practice Cancer Chemotherapy in Clinical Practice Terry Priestman Terry Priestman, MD, FRCP, FRCR New Cross Hospital Wolverhampton UK British Library Cataloguing in Publication
More informationSeptember 30, Eric BASTINGS, MD. Acting Director Division of Neurology Products (DNP) Center for Drug Evaluation and Research (CDER)
ISCTM Autumn Conference Options and methods to improve cognitive assessment in clinical trials of AD and its precursors September 30, 2013 Eric BASTINGS, MD Acting Director Division of Neurology Products
More informationPRI-MED UPDATES Long Beach, CA October 10-11, 2008 PROGRAM DIRECTORY
PRI-MED UPDATES Long Beach, CA October 10-11, 2008 PROGRAM DIRECTORY Accreditation Information Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME), which
More informationCome leggere i risultati di uno studio clinico How to read the results of a clinical trial
Come leggere i risultati di uno studio clinico How to read the results of a clinical trial Massimo Di Maio SCDU Oncologia Medica, AO Mauriziano, Torino Dipartimento di Oncologia Università di Torino massimo.dimaio@unito.it
More informationIntensity: 0-10 (10 is the worse pain you have ever experienced in your life that you would want to jump from a building, 0 is no pain)
Patient Questionnaire: Name: Date: Occupation: Date of Birth: Age: Sex: Male Female Referring Physician: Chief Complaint: Describe your Pain: sudden onset gradual constant intermittent worsening improving
More informationPatient Information. Patient Name: DOB: Last First M.I. Home Address: City: State: Zip: Home Phn: Cell Phn: Alt. Phn: SSN:
Dr. Alvin Huang, M.D., F.A.C.E. 1650 W. Rosedale St. Suite 301, Fort Worth TX 76104 (P) 817-259-4333 (F) 817-820-0303 Patient Information Patient Name: DOB: Last First M.I. Home Address: City:_ State:
More informationMeasuring Long-Term Conditions in Scotland - A summary report
Measuring Long-Term Conditions in Scotland - A summary report Introduction This summary report provides insight into: What are the most common long-term conditions in Scotland? What is the population prevalence
More informationPerformance Outcome Measures: A Regulatory Perspective
Performance Outcome Measures: A Regulatory Perspective International Society for Pharmacoeconomics and Outcomes Research (ISPOR) May 18, 2015 Ashley F. Slagle, MS, PhD Study Endpoints and Labeling Development
More informationCHRONIC MEDICATION PROGRAMME INCLUDES PRESCRIBED MINIMUM BENEFIT CHRONIC DISEASE LIST (CDL)
CHRONIC MEDICATION PROGRAMME INCLUDES PRESCRIBED MINIMUM BENEFIT CHRONIC DISEASE LIST (CDL) A. GENERAL INFORMATION LIST OF CHRONIC CONDITIONS Conditions covered under KeyHealth s chronic medication benefit
More informationEnd-of-life care in oxygen-dependent COPD and cancer: a national population-based study.
End-of-life care in oxygen-dependent COPD and cancer: a national population-based study. Ahmadi, Zainab; Lundström, Staffan; Janson, Christer; Strang, Peter; Emtner, Margareta; Currow, David C; Ekström,
More informationExpert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007 TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Selecting Initial Therapy
More informationPublic Dissemination Effective: January 2018
Board of Pharmacy Specialties Board Certified Geriatric Pharmacist (BCGP) Detailed Content Outline 1. GENERAL PRINCIPLES OF AGING (20%) A. Apply the knowledge of physiologic changes associated with aging
More informationPragmatic frameworks and systematic approaches to intervention design. Anne Sales
Pragmatic frameworks and systematic approaches to intervention design Anne Sales salesann@umich.edu Some thoughts about healthcare and how it works You need to deal with issues related to professionalism
More informationBending the Cost Curve Through Comparative Effectiveness Research. ASCO 2012 Sean Tunis MD, MSc June 2, 2012
Bending the Cost Curve Through Comparative Effectiveness Research ASCO 2012 Sean Tunis MD, MSc June 2, 2012 Evidence Summary: Radiation Therapy for Comparisons Clinically Localized Prostate Cancer Disease
More informationImproving Type 2 Diabetes Therapy Adherence and Persistence in Mexico
July 2016 Improving Type 2 Diabetes Therapy Adherence and Persistence in Mexico Appendix PATIENT ACTIVATION Introduction This Appendix document provides supporting material for the report entitled Improving
More informationHealth and Quality of Life Outcomes BioMed Central
Health and Quality of Life Outcomes BioMed Central Guidelines Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance U.S.
More informationIncorporating the patient voice in sarcoma research:
Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous patient groep? Olga Husson PhD Institute of Cancer Research, Division of Clinical
More informationGlobal Action Against Dementia: Finding a Path Forward and the World Dementia Council
Global Action Against Dementia: Finding a Path Forward and the World Dementia Council Raj Long MBPsS MSc Vice Chair World Dementia Council ASAD Hangzhou October 2016 1 Overview 1. Global State of Dementia
More informationThe MASCC Guidelines Policy
The MASCC Guidelines Policy Recommendations for MASCC Guideline Construction and the Endorsement of Externally Generated Guidelines Preamble MASCC recognizes that providing supportive care facilitates
More information10th anniversary of 1st validated CaPspecific
Quality of Life after Treatment of Localised Prostate Cancer Dr Jeremy Grummet Clinical Uro-Oncology Fellow May 28, 2008 1 Why? This is important May be viewed as soft science Until we know which treatment
More informationBenefit/Risk Assessment A Critical Need
Benefit/Risk Assessment A Critical Need Christy Chuang-Stein, PhD Statistics, Pfizer Inc Society for Clinical Trials 30 th Annual Meeting 1 Some Basic Facts All pharmaceutical products have side effects
More informationHeart Failure Transitions of Care SJMH - Ann Arbor
Heart Failure Transitions of Care SJMH - Ann Arbor March 4, 2013 Cecelia Montoye, RN, MSN Reducing 30 Day Heart Failure Readmissions: SJMH Ann Arbor See you in 7 Measures Process Measure #4: Identify and
More informationResponding to the Spirit of 21 st Century Cures Legislation
Responding to the Spirit of 21 st Century Cures Legislation Clinical Research Forum Industry Forum September 25, 2017 Joe Selby, MD MPH Executive Director, PCORI For Today Doing Research Differently: Patient-Centered
More informationQualitative Methods and Patient Reported Outcome Measures. Susan C Pitt, MD, MPHS Assistant Professor of Surgery University of Wisconsin
Qualitative Methods and Patient Reported Outcome Measures Susan C Pitt, MD, MPHS Assistant Professor of Surgery University of Wisconsin Disclosures None Overview What is it? When is it useful? Why do it?
More informationInterpretation Clinical significance: what does it mean?
Interpretation Clinical significance: what does it mean? Patrick Marquis, MD, MBA Mapi Values - Boston DIA workshop Assessing Treatment Impact Using PROs: Challenges in Study Design, Conduct and Analysis
More informationTechnology-Enabled Dementia Care
Technology-Enabled Dementia Care Reducing Facility Utilization for Patients with Dementia Ceresti Health 2888 Loker Avenue, Ste. 209 Carlsbad, CA 92010 760.453.0997 www.ceresti.com Jan-19 v1.3 by Empowering
More informationCONTENT OUTLINE FOR THE PHARMACOTHERAPY CERTIFICATION EXAMINATION
CONTENT OUTLINE FOR THE PHARMACOTHERAPY CERTIFICATION EXAMINATION The following domains, tasks and knowledge statements were delineated by the BPS Specialty Council on Pharmacotherapy and validated through
More informationINTERNAL MEDICINE FOR PRIMARY CARE: CARDIOLOGY/INFECTIOUS DISEASE/NEUROLOGY/PULMONARY
INTERNAL MEDICINE FOR PRIMARY CARE: CARDIOLOGY/INFECTIOUS DISEASE/NEUROLOGY/PULMONARY Barcelona, Spain Majestic Hotel & Spa Barcelona May 25 28, 2015 Monday, May 25th: 7:30 am 8:00 am Registration and
More informationThe place for treatments of associated neuropsychiatric and other symptoms
The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public
More informationSupplementary Online Content
Supplementary Online Content Oeffinger KC, Fontham ETH, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. doi:10.1001/jama.2015.12783.
More informationDIA Workshop: «Pharmacoeconomic and Quality of Life Labeling and Promotional Claims: A Global Update»
DIA Workshop: «Pharmacoeconomic and Quality of Life Labeling and Promotional Claims: A Global Update» October 29-30, 2001 Hyatt Regency Philadelphia, PA, USA Role of Health-Related Quality of Life (HRQL)
More informationUpdate on CDER s Drug Development Tool Qualification Program
Update on CDER s Drug Development Tool Qualification Program ShaAvhree Buckman-Garner, M.D., Ph.D. Director Office of Translational Sciences Center for Drug Evaluation and Research U.S. Food and Drug Administration
More informationICH E9 (R1) Addendum on Estimands and Sensitivity Analysis
ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis Rob Hemmings Mouna Akacha MHRA + ICH E9 (R1) Expert Working Group Novartis 1 Disclaimer (I) Not a statistical topic This impacts every clinical
More informationMJFF S VISION FOR PARTNERING WITH PATIENTS. Sohini Chowdhury The Michael J. Fox Foundation
MJFF S VISION FOR PARTNERING WITH PATIENTS Sohini Chowdhury The Michael J. Fox Foundation OUR SINGLE, URGENT GOAL: CURE PARKINSON S DISEASE MJFF s Mission The Michael J. Fox Foundation is dedicated to
More informationThe Treatment of Rett Syndrome with Trofinetide (NNZ-2566): Past, Present, Future. Daniel Glaze, MD Baylor College of Medicine
The Treatment of Rett Syndrome with Trofinetide (NNZ-2566): Past, Present, Future Daniel Glaze, MD Baylor College of Medicine Multicenter Trials of Trofinetide Past: Neu-2566-RETT-001 Phase 2 in Adolescents
More informationCOVERAGE WITH EVIDENCE DEVELOPMENT
COVERAGE WITH EVIDENCE DEVELOPMENT OVERVIEW AND USE TO PROMOTE BIOMARKER DEVELOPMENT IOM National Cancer Policy Forum Sean Tunis, MD, MSc November 10, 2014 CED DEFINITION AND PURPOSE Reimbursement that
More informationPerformance Improvement Project Implementation & Submission Tool
PLANNING TEMPLATE Performance Improvement Project Implementation & Submission Tool INTRODUCTION & INSTRUCTION This tool provides a structure for development and submission of Performance Improvement Projects
More informationSafety Pharmacology Society Webinar: Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North America
Safety Pharmacology Society Webinar: Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North America Agenda Introduction GI presentation rescheduled Upcoming SPS
More informationMarcia Boehmke Jean K. Brown, Ph.D. Ruth McCorkle M. Tish Knobf Bill Wu. The State University of New York Amherst, NY
AD Award Number: W81XWH-04-1-0487 TITLE: The Development of a Comprehensive Instrument to Measure Symptoms and Symptom Distress in Women After Treatment for Breast Cancer PRINCIPAL INVESTIGATOR: Marcia
More informationMeasuring Patient Outcomes:
Measuring Patient Outcomes: Interplay of science, policy and marketing Chapel Hill, November 22, 22 Dr. Claire Bombardier Professor of Medicine, University of Toronto Senior Scientist, Institute for Work
More information